ReviewFrontiers in medicine2023
Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 28 citations in OpenAlex.
- Rewriting Inflammation in IBD: Lipidomics from Pathogenesis to Clinical Application.Microorganisms · 2026Review
- Article
- A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?Current opinion in lipidology · 2026Review
- Inflammatory, Nutritional, and Atherogenic Profiles Associated with Histologic Activity in Inflammatory Bowel Disease.Biomedicines · 2026Article
- Ulcerative colitis: signaling pathways, therapeutic targets and interventional strategies.Signal transduction and targeted therapy · 2026Review
- Loss of E3 ligase Ube4A Disrupts Colon Homeostasis and Accelerates Experimental Colitis via Altered Lipid Handling.bioRxiv : the preprint server for biology · 2026Article
- Association between metabolic syndrome and inflammatory bowel disease: a bidirectional two-sample Mendelian randomized study.Archives of medical science : AMS · 2026Article
- eCONUT-UC for nutritional screening and malnutrition identification in ulcerative colitis.Frontiers in nutrition · 2026Article
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- Lipoprotein (a) and inflammatory bowel disease: a systematic review and meta-analysis.Annals of gastroenterology · 2026Article
- The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn's disease.Frontiers in immunology · 2026Review
- Human gut commensalGut microbes · 2025Article
- Serum uric acid to high‑density lipoprotein cholesterol ratio as a novel predictor of diabetic nephropathy: a cross‑sectional analysis of NHANES 2011-2018.Clinical and experimental medicine · 2025Article
- Decline in Serum Lysophosphatidylcholine Species in Patients with Severe Inflammatory Bowel Disease.Journal of clinical medicine · 2025Article
- Pathophysiological Links Between Inflammatory Bowel Disease and Cardiovascular Disease: The Role of Dysbiosis and Emerging Biomarkers.Biomedicines · 2025Review
- Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review.World journal of gastroenterology · 2025Review
- Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.Advances in therapy · 2025Review
- Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity.International journal of molecular sciences · 2025Article
- Crohn's disease but not ulcerative colitis elevated risk of end-stage renal disease and mortality: A Taiwan retrospective cohort study.Medicine · 2025Observational
- Blood Lipid Levels and Their Value as Markers of Disease Activity in Severe Ulcerative Colitis.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum lipid levels seem to be abnormal in Inflammatory bowel disease (IBD). However, the specific manifestation of abnormal serum lipid levels in IBD are heterogeneous among studies and have not been sufficiently determined yet. Methods: PubMed, EMBASE, and Cochrane Library databases were searched. Serum lipid levels were compared between IBD patients and Health individuals, Crohn's (CD) and ulcerative colitis (UC), active and inactive, mild and non-mild patients, respectively. Meta-analyses were performed by using a random-effect model. Weight mean difference (WMD) with 95% confidence intervals (CIs) were calculated. Results: Overall, 53 studies were included. Compared with healthy controls, IBD patients had significantly lower TC (WMD = -0.506, 95%CI = -0.674 to -0.338, Conclusion: The overall level of serum lipids in IBD patients is lower than that of healthy individuals and is negatively associated with disease severity. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42022383885.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.